Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 78760-60-8 | MDL No. : | MFCD11977436 |
Formula : | C13H10N2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FCECYLUEYDBZHV-UHFFFAOYSA-N |
M.W : | 210.23 | Pubchem ID : | 15574701 |
Synonyms : |
|
Num. heavy atoms : | 16 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.08 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 59.93 |
TPSA : | 45.91 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.9 cm/s |
Log Po/w (iLOGP) : | 2.24 |
Log Po/w (XLOGP3) : | 2.37 |
Log Po/w (WLOGP) : | 2.38 |
Log Po/w (MLOGP) : | 1.07 |
Log Po/w (SILICOS-IT) : | 2.84 |
Consensus Log Po/w : | 2.18 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.99 |
Solubility : | 0.213 mg/ml ; 0.00101 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.97 |
Solubility : | 0.223 mg/ml ; 0.00106 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.78 |
Solubility : | 0.00349 mg/ml ; 0.0000166 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.23 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280 | UN#: | N/A |
Hazard Statements: | H302-H312-H332 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
85% | Stage #1: With potassium carbonate In N,N-dimethyl-formamide at 60℃; for 0.5 h; Stage #2: at 66℃; for 1 h; |
Step l:5-Benzyloxy-pyridine-2-carbonitrile (3_60_2) [00482] A mixture of 5-hydroxy-pyridine-2-carbonitrile 3_60_1 (14 g, 116 mmol) and potassium carbonate (32.2 g, 233 mmol) in Ν,Ν-dimethylformamide (140 mL) was heated at 60°C for 0.5 hours. Benzylbromide (13.9 g, 116 mmol) was added and the mixture was stirred at 66°C for 1 hour, and filtered and the filtrate was concentrated, extracted with ethyl acetate, washed with brine, dried over sodium sulfate and concentrated. The residue was triturated with diethyl ether and hexanes to give a precipitate, which was collected to give compound 3_60_2 (21 g, 85 percent yield) as a solid. [00483] NMR (400 MHz, DMSO-d6): δ = 5.27 (s, 2H), 7.33-7.50 (m, 5H), 7.65 (dd, J=8.8, 2.9 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 8.50 (d, J = 3.2 Hz, 1H). |
[ 166672-22-6 ]
5-(Benzyloxy)pyrimidine-2-carbonitrile
Similarity: 0.72
[ 166672-22-6 ]
5-(Benzyloxy)pyrimidine-2-carbonitrile
Similarity: 0.72
[ 166672-22-6 ]
5-(Benzyloxy)pyrimidine-2-carbonitrile
Similarity: 0.72